Assert-IQ vs ZEUS System (Zio Watch)
AI Verdict
Choose Assert-IQ if…
Choose Assert-IQ if your patient requires exceptionally long-term, continuous cardiac monitoring, potentially for several years, to detect rare or asymptomatic arrhythmias that might be missed by shorter-duration external monitors. This insertable cardiac monitor is ideal for comprehensive, discreet monitoring where a minimally invasive, long-lasting solution is preferred for definitive diagnosis and management.
View Assert-IQ →Choose ZEUS System (Zio Watch) if…
Choose the ZEUS System (Zio Watch) if you need a convenient, non-invasive wearable solution for continuous cardiac monitoring for up to 14 days, especially when the primary concern is detecting and characterizing Atrial Fibrillation (AFib) burden. This system is well-suited for patients who benefit from a user-friendly external device with AI-powered analysis and a patient app for symptom logging and engagement.
View ZEUS System (Zio Watch) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Assert-IQ | ZEUS System (Zio Watch) |
|---|---|---|
| Pricing | Enterprise | Contact vendor |
| Deployment | Hybrid | Cloud-based system with a wearable device |
| FDA Status | Cleared AI-estimated | 1 AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ZEUS System (Zio Watch)Tool B offers a non-invasive wearable device and comprehensive mobile applications for both patients and providers, enhancing ease of use and engagement. Tool A, while minimally invasive, lacks explicit mobile app support for patient and clinician interaction, relying on a patient activator.
Clinical Value
Assert-IQTool A provides significantly longer continuous cardiac monitoring (up to 6 years) compared to Tool B's 14 days, offering a substantial advantage for diagnosing rare or intermittent arrhythmias. This extended monitoring period can lead to more definitive diagnoses for complex cases.
Pricing & Value
TieBoth tools require direct contact with the vendor for pricing information, and neither offers a free trial. Without transparent pricing or detailed value propositions, it is not possible to determine a clear winner in this dimension.
Enterprise Readiness
Assert-IQTool A explicitly targets large health systems, hospitals, and cardiology clinics, and offers data export capabilities, which are crucial for enterprise integration. Its hybrid deployment model may also offer flexibility for diverse IT infrastructures.
Innovation
Assert-IQTool A's innovation in providing ultra-long-term continuous cardiac monitoring (up to 6 years) via an insertable device represents a significant advancement in diagnostic duration and capability. While Tool B's wearable AI is innovative, the extended monitoring period of Tool A addresses a more challenging clinical need.
Support & Docs
TieThe provided structured facts do not contain specific information regarding the level or quality of support and documentation for either tool. Therefore, it is not possible to differentiate between them on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Assert-IQ | ZEUS System (Zio Watch) |
|---|---|---|
| Name | Assert-IQ | ZEUS System (Zio Watch) |
| Company | Abbott Medical | iRhythm Technologies |
| Description | The Assert-IQu2122 Insertable Cardiac Monitor (ICM) system provides long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders. | iRhythm Technologies' ZEUS System (Zio Watch) is an FDA-cleared, AI-powered wearable for long-term continuous cardiac monitoring, specifically designed to detect and characterize Atrial Fibrillation (AFib) and other cardiac arrhythmias, providing actionable insights for physicians. |
| Mobile App | none | ZioSuiteu00ae portal and provider mobile app for report interpretation and patient management, MyZiou00ae patient app for digital symptom logging, educational content, and reminders |
| Key Features | Long-term continuous cardiac monitoring (up to 6 years), Advanced arrhythmia detection algorithms, Bluetoothu00ae Low Energy data transmission, Secure cloud-based data platform, Remote monitoring capabilities, Proactive clinician alerts, Patient activator for symptom logging, Minimally invasive insertion | Wearable biosensor (Zio Watch) for continuous ECG and PPG data collection, AI-powered algorithm (ZEUS System) for advanced arrhythmia detection and analysis, Long-term continuous monitoring for up to 14 days, Detects and characterizes Atrial Fibrillation (AFib) burden, Cloud-based data analytics and processing, Clinically actionable reports with high physician agreement (99%), ZioSuiteu00ae portal and provider mobile app for report interpretation and patient management, MyZiou00ae patient app for digital symptom logging, educational content, and reminders |
| Monitoring Duration | up to 6 years | up to 14 days |
Videos
Demos, reviews, and walkthroughs featuring Assert-IQ and ZEUS System (Zio Watch).
Frequently Asked Questions
More Comparisons
More matchups featuring Assert-IQ or ZEUS System (Zio Watch)
Backers
Who funded each tool's parent company.